Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a new release version. This update is an internal version change and does not modify the study content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedCore page content identifying investigators, sponsor, collaborators, and other study personnel was removed, along with multiple study record metadata sections. A new Revision: v3.6.5 tag appears, indicating a version update to the page.SummaryDifference17%

- Check52 days agoChange DetectedThe page's revision version was updated from v3.6.3 to v3.6.4, indicating a new deployment. This update does not modify the study details or functionality presented to users.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page version was updated from v3.6.2 to v3.6.3. This represents a routine update that does not alter study information or how a user interacts with the page.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page footer now shows Revision: v3.6.2, replacing the previous Revision: v3.6.0; this indicates a new build of the page template rather than substantive changes to the study information.SummaryDifference0.1%

- Check95 days agoChange DetectedA recruitment status line indicating no participant enrollment was added. Additionally, new help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), the Interventional label formatting was refined from 'Intervention / Treatment' to 'Intervention/Treatment', and a site revision stamp 'Revision: v3.6.0' was introduced.SummaryDifference0.6%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.